


Supplemental Figure 1. HERO Registry and HERO-HCQ Trial Timeline



Supplemental Table 1. Participating PCORnet HERO-HCQ Trial Sites

AdventHealth Orlando
Allina Health
Baylor Scott and White Memorial Hospital
Children's Hospital Colorado
Clinical Trials Center of Middle Tennessee
Columbia University Medical Center
Duke University Hospital
Hospital for Special Surgery
Johns Hopkins Hospital
Marshfield Clinic
Mayo Clinic
Michigan Medicine
New York Presbyterian/Weill Cornell Medical Center
Northwestern University
Ochsner Clinic Foundation
Rush University Medical Center
Seattle Children's Hospital
Tampa General Hospital
Temple University Hospital
The Ohio State University Wexner Medical Center
University Medical Center- New Orleans
University of Florida Health
University of Florida Health Central Florida
University of Florida Jacksonville Shands Medical Center
University of Iowa
University of Kansas Medical Center
University of Miami Miller School of Medicine
University of Missouri - Columbia
University of Nebraska Medical Center
University of North Carolina at Chapel Hill
University of Pittsburgh School of Medicine
University of Texas Southwestern Medical Center Dallas
Vanderbilt University Medical Center
Wake Forest Baptist Medical Center

Supplemental Table 2. Comparison of Confidence Interval (CI) Estimates for the Primary Analysis

CI Method	95% CI (% scale)
Miettinen-Nurminen	-4.60, 0.87
Chang-Zhang	-4.61, 0.90
Agresti-Caffo	-4.55, 0.88
Hauck-Anderson	-4.61, 0.94
Miettinen-Nurminen-Mee	-4.60, 0.87
Newcombe	-4.59, 0.88
Newcombe (corrected)	-4.69, 0.99
Wald (corrected)	-4.68, 1.01

Note: the point estimate is -1.84% favoring HCQ vs. placebo at Day 30. The 2-sided Fisher's exact p-value is 0.20.

Supplemental Table 3. Comparison of COVID PREP and HERO-HCQ studies

	COVID PREP (NCT04328467)	HERO-HCQ (NCT04334148)
Randomization ratio	2:2:1:1 (the placebo arms were pooled)	1:1
HCQ dosage	Loading dose of 400 mg (two 200-mg tablets) twice separated by 6-8 hours followed by (i) 400 mg (two 200-mg tablets) once weekly for 12 weeks or (ii) 400 mg (two 200-mg tablets) twice weekly for 12 weeks	600-mg loading dose of study drug twice on the first day, followed by 400 mg daily for 29 days
Maximum follow-up	3 months	Treatment period for 30 days with follow-up at Day 60
Planned sample size	~3,150 HCW (1050 per arm)	15,000 HCW (7500 per arm)
Final sample size (% of planned)	1483 (47.2%)	1359 (9.1%)
HCQ primary endpoint event rate	58/989 (5.9%)	41/683 (6.0%)
Placebo primary endpoint event rate	39/494 (7.9%)	53/676 (7.8%)

Mantel–Haenszel Common Odds Ratio = **0.74 (95% CI 0.55 to 1.00)**, **p= 0.046**. Breslow-Day Test of Homogeneity p-value= 0.92.